8-K: Blade Air Mobility Achieves Passenger Segment Profitability Ahead of Schedule, Q3 Results Show Strong Growth

Blade Air Mobility reports a significant increase in operating cash flow and achieves trailing twelve-month profitability in its Passenger segment, exceeding previous guidance.

Summary

• Blade Air Mobility announced its financial results for the third quarter of 2024, showing positive trends in key areas.
• Operating cash flow increased by $4.3 million to $6.4 million in Q3 2024.
• Free cash flow, before aircraft acquisitions, rose by $2.4 million to $3.7 million in Q3 2024.
• The Medical segment's Adjusted EBITDA improved by 15.1% compared to the prior year.
• The Passenger segment achieved trailing twelve-month Adjusted EBITDA profitability in Q3 2024, ahead of the previously projected full-year profitability by the end of 2025.
• Net loss increased by $2.2 million year-over-year to $(2.0) million in Q3 2024, while Adjusted EBITDA improved by $3.4 million to $4.2 million.
• The company reaffirmed its guidance for positive Adjusted EBITDA in 2024 and double-digit millions of Adjusted EBITDA in 2025.
• A strategic alliance with OrganOx was announced to enhance the distribution of their metra perfusion device.
• Total revenue increased by 4.8% to $74.9 million in Q3 2024 compared to $71.4 million in the prior year period.
• Flight Profit increased by 27.3% to $19.8 million in Q3 2024.
• Flight Margin improved to 26.5% in the current quarter from 21.8% in the prior year period.
• Medical revenue increased by 7.8% to $36.1 million, while Short Distance revenue increased by 6.5% to $32.4 million.
• The company ended Q3 2024 with $136.3 million in cash and short-term investments.

Sentiment

Score: 8

Explanation: The document presents a generally positive outlook with strong improvements in key financial metrics and strategic initiatives. The achievement of passenger segment profitability ahead of schedule is a significant positive. However, there are some negative aspects such as the increase in net loss and the impact of lower medical flight volumes, which temper the overall sentiment.

Positives

• The Passenger segment achieved profitability significantly ahead of schedule.
• Operating and free cash flow showed substantial improvements.
• Adjusted EBITDA saw a significant year-over-year increase.
• The Medical segment continues to grow and improve its profitability.
• The strategic alliance with OrganOx is expected to enhance the company's medical logistics capabilities.
• The company is expanding its owned aircraft fleet, which is expected to improve profitability and enable new contracts.
• Blade's organ placement service continues to gain market share.
• The company has a strong cash position of $136.3 million.

Negatives

• Net loss increased by $2.2 million year-over-year to $(2.0) million in Q3 2024.
• Medical revenue decreased (5.9)% sequentially versus Q2 2024 due to lower air trip volume and a reduction in block hours per air trip.
• Jet and Other revenue decreased 15.0% due to a decline in revenue per flight as charter industry pricing normalized.
• Lower medical flight volumes in Q3 led to negative operating leverage.
• Above average expenses on the owned aircraft fleet, including entry into service delays, led to lower Medical Segment Adjusted EBITDA margins in Q3 2024 versus Q2 2024.

Risks

• The company is subject to fluctuations in financial results.
• The company relies on third-party operators, which could be subject to disruptions.
• The company is exposed to risks related to the adoption of EVA technology.
• The company is subject to competition and changes in consumer preferences.
• The company is exposed to risks related to accidents involving small aircraft, helicopters or charter flights.
• The company is subject to regulatory obstacles in local governments.
• The company is subject to the effects of climate change, including potential increased impacts of severe weather and regulatory activity.
• The company is subject to the availability of aircraft fuel.

Future Outlook

The company expects revenue of $240 million to $250 million and positive Adjusted EBITDA for the full year 2024. For 2025, they anticipate double-digit Medical revenue growth, Passenger revenue of $85 million to $95 million, and double-digit millions of Adjusted EBITDA.

Management Comments

• Rob Wiesenthal, Blade's Chief Executive Officer, stated that the company reached an important milestone in the Passenger Business, achieving positive Segment Adjusted EBITDA on a trailing twelve month basis, more than a year ahead of investor guidance.
• Wiesenthal believes Blade is better positioned for the transition to Electric Vertical Aircraft than any other Urban Air Mobility company.
• Will Heyburn, Chief Financial Officer, noted the great conversion of Adjusted EBITDA to Free Cash Flow, Before Aircraft Acquisitions.
• Melissa Tomkiel, President, mentioned the acquisition of two additional aircraft expected to enter service by early 2025.

Industry Context

This announcement comes as the urban air mobility sector is gaining more attention, with companies like Blade positioning themselves for the transition to electric vertical aircraft. The strategic alliance with OrganOx highlights the growing importance of logistics in the medical transportation sector. The results also reflect the challenges of managing a diverse business with both passenger and medical segments, and the impact of external factors such as transplant volumes and charter pricing.

Comparison to Industry Standards

• Blade's achievement of Passenger segment profitability ahead of schedule is a positive sign compared to other urban air mobility companies that are still struggling to achieve profitability.
• The 15.1% improvement in Medical Segment Adjusted EBITDA is a strong result, especially considering the softer than expected Q3 for US organ transplant volumes, indicating a competitive advantage in this niche market.
• While the company does not directly compare itself to specific competitors, the focus on asset ownership and strategic partnerships like the one with OrganOx is a strategy that differentiates it from other players in the space.
• The company's focus on transitioning to EVA technology aligns with the broader industry trend towards sustainable and cost-effective air transportation.

Stakeholder Impact

• Shareholders will likely view the achievement of passenger segment profitability and improved cash flow positively.
• Employees may benefit from the company's growth and strategic initiatives.
• Customers in the medical sector will benefit from the improved logistics and expanded services.
• Customers in the passenger sector will benefit from the improved profitability and service offerings.
• Suppliers and creditors may see the company as a more stable and reliable partner.

Next Steps

• The company will continue to integrate the newly acquired aircraft into its fleet.
• The company will focus on expanding its medical organ placement service.
• The company will continue to develop its strategic alliance with OrganOx.
• The company will continue to work towards the transition to Electric Vertical Aircraft.

Key Dates

Keywords

Air Mobility, Urban Air Mobility, Helicopter, eVTOL, Medical Transport, Organ Transport, Adjusted EBITDA, Cash Flow, Flight Profit, Passenger Transport